US 10,376,573 B2
Vaccines for serogroup X meningococcus
Mariagrazia Pizza, Siena (IT); Peter Dull, Seattle, WA (US); Marzia Monica Giuliani, Siena (IT); Muhamed-Kheir Taha, Saint Maur des Fosses (FR); Eva Hong, Maisons-Alfort (FR); and Ala-Eddine Deghmane, Gagny (FR)
Assigned to GlaxoSmithKline Biologicals SA, Rixensart (BE); and Institut Pasteur, Paris (FR)
Appl. No. 14/407,987
Filed by GlaxoSmithKline Biologicals SA, Rixensart (BE); and Institut Pasteur, Paris (FR)
PCT Filed Jun. 14, 2013, PCT No. PCT/IB2013/054886
§ 371(c)(1), (2) Date Dec. 15, 2014,
PCT Pub. No. WO2013/186753, PCT Pub. Date Dec. 19, 2013.
Claims priority of provisional application 61/659,595, filed on Jun. 14, 2012.
Prior Publication US 2016/0166674 A1, Jun. 16, 2016
Int. Cl. A61K 39/095 (2006.01); A61K 39/39 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/095 (2013.01) [A61K 2039/54 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/70 (2013.01)] 13 Claims
 
1. A method for immunizing a subject in need thereof against serogroup X meningococcus by administering to the subject a composition comprising a meningococcal fHbp antigen and an aluminum salt adjuvant; wherein the meningococcal fHbp antigen comprises amino acid sequence SEQ ID NO: 7, wherein the composition either (a) is free from meningococcal outer membrane vesicles or (b) includes meningococcal outer membrane vesicles, and the fHbp antigen is present in the composition in soluble form, wherein the fHbp antigen is not conjugated to a meningococcal polysaccharide, and wherein the composition does not contain un-conjugated meningococcal polysaccharides.